Antibiotics have been a key component of modern medicine for decades. A critical question is why not enough antibacterials are being developed to tackle the growing challenge of drug-resistant infections. While current innovation in the early preclinical pipeline is encouraging, the journey for any new antibiotic is burdened with multiple challenges across its early and late development path. In this viewpoint, we explore the barriers to antibiotic development and how the Wellcome Trust is addressing these problems and working toward developing long-term solutions to facilitate a sustainable R&D ecosystem.

中文翻译：

---

惠康信托公司抗药性感染优先计划的观点：建立一个可持续的研发生态系统以满足全球对抗生素的需求。

数十年来，抗生素一直是现代医学的重要组成部分。一个关键问题是，为什么没有开发出足够的抗菌素来应对日益增长的耐药性感染挑战。尽管当前在临床前早期研发中的创新令人鼓舞，但任何新抗生素的开发过程在其早期和晚期开发路径上都面临着诸多挑战。用这种观点，我们探索了抗生素开发的障碍，以及惠康基金会如何解决这些问题，并致力于开发长期解决方案以促进可持续的研发生态系统。